Autopsy report · NCT03385395

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

“IND has been closed.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Octapharma

Sponsor type

Industry

Conditions

Alpha 1-Antitrypsin Deficiency

Interventions

OctaAlpha1; Glassia

Participants

0

Trials that died the same way

• Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis
  “IND issues” (63% match in meaning)
• Phase 1 meCS6 + LT(R192G) Vaccine Study
  “IND was terminated for being inactive for more than five years” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.